Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ movement disorders ‐ at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
1 finding from 1 review
Death · patients with schizophrenia
Comparison 1: PERPHENAZINE showed no clear difference in death compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Response to treatment ‐ medium term · patients with schizophrenia
Trifluoperazine showed no clear difference in response to treatment ‐ medium term compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Adverse effects/events: at least 1 adverse effect ‐ as defined by individual studies. · patients with schizophrenia
Trifluoperazine showed no clear difference in adverse events: 1. General ‐ at least one adverse effect compared with low‐potency antipsychotic drugs (moderate certainty).
1 finding from 1 review
Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
Trifluoperazine showed no clear difference in adverse events: 2.a. Specific ‐ movement disorders ‐ at least one… compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Death · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Well‐being and quality of life Personal Wellbeing Index (PWI‐C) . Scale from: 0 to 77 (low = poor) · patients with schizophrenia
It is very uncertain whether horticultural therapy plus standard care changes well‐being and quality of life Personal Wellbeing Index (PWI‐C) .… compared with standard care alone (very low certainty).
1 finding from 1 review
Clinical global response · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Level of functioning · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Physical fitness · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · patients with schizophrenia
It is very uncertain whether horticultural therapy plus standard care changes satisfaction with treatment Leaving the study early compared with standard care alone (very low certainty).
1 finding from 1 review
Adverse effect · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Mental state and behaviour DASS21. Scale from: 0 to 84 (high = poor) · patients with schizophrenia
It is very uncertain whether horticultural therapy plus standard care changes mental state and behaviour DASS21. Scale from: 0 to 84 (high = poor) compared with standard care alone (very low certainty).
1 finding from 1 review
Hospital admissions · patients with schizophrenia
It is very uncertain whether BRIEF FAMILY INTERVENTION changes service utilisation ‐ hospital admission ‐ medium to long term… compared with STANDARD CARE (very low certainty).
1 finding from 1 review
Service use: 1. Average number of days in hospital per month ‐ by about 24 months · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found